Emir Muzurović

dr sci med Emir Muzurović

saradnik u nastavi dr | Medicinski fakultet | honorarno

Emir Muzurović emir@ucg.ac.me   dr Emir Muzurović, rođen 26.10.1981.godine u Bjelom Polju, Crna Gora Obrazovanje: - 2007- završio Medicinski fakultet, UCG, prosječna ocjena 9,53. - 2013 godine položio završni specijalistički ispit, specijalizacija Interne medicine, Medicinski fakultet u Beogradu, ocjena 10. - 2017 godine položio završni ispit  uže specijalizacije Endokrinologije, Medicinski fakultet u...

Nastava

Jedinica Program Tip Sem. Predmet P x GP V x GV L x GL

Izabrane publikacije

Godina Kategorija Autori Naslov Izvor
2024SCI, SCIE, SSCI, A&HCI
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, Marlene Chakhtoura, Michael A. Hill, Dimitri P. Mikhailidis and Christos S. MantzorosSteatotic Liver Disease: Pathophysiology and Emerging PharmacotherapiesPharmacological Reviews
2024SCI, SCIE, SSCI, A&HCI
Muzurović E, Maćešić M, Kavarić S. Liver Fibrosis and Atherosclerosis, a Consequence of Metabolic Dysfunction-Do They Share a Similar Pathophysiological Background?Angiology
2024SCI, SCIE, SSCI, A&HCI
Muzurović E, Borozan S, Rizzo, M.Clinical impact of genetic testing for lipid disordersCurrent Opinion in Cardiology
2024SCI, SCIE, SSCI, A&HCI
K Zečević, Š Volčanšek, N Katsiki, M Rizzo, T Miličević Milardović, A Pantea Stoian, M Banach, E MuzurovićMaturity-onset diabetes of the young (MODY) - in search of ideal diagnostic criteria and precise treatmentProgress in Cardiovascular Diseases
2024SCI, SCIE, SSCI, A&HCI
Janez A, Muzurovic E, Bogdanski P, Czupryniak L, Fabryova L, Fras Z, Guja C, Haluzik M, Kempler P, Lalic N, Mullerova D, Stoian AP, Papanas N, Rahelic D, Silva-Nunes J, Tankova T, Yumuk V, Rizzo M.Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert GroupDiabetes Ther.
2024SCI, SCIE, SSCI, A&HCI
Sanja Borozan, Snežana Vujošević, Dimitri P. Mikhailidis and Emir MuzurovićMetabolic Dysfunction-Associated Steatohepatitis and Cardiovascular Disease Prevention: Is Resmetirom Useful?Current Vascular Pharmacology
2024SCI, SCIE, SSCI, A&HCI
Volčanšek Š, Janež A, Rizzo M, Muzurović E. Monitoring the liver as a part of the cardio-renal-metabolic continuum - What is cooking and burning with non-invasive tests and treatment options? J Diabetes Complications.
2023SCI, SCIE, SSCI, A&HCI
Muzurović Emir*, Polyzos Stergios, Mikhailidis Dimitri, Borozan Sanja, Novosel Dušanka, Cmiljanić Oleg, Kadić Nataša and Mantzoros ChristosNon-alcoholic fatty liver disease in childrenCurrent Vascular Pharmacology
2023SCI, SCIE, SSCI, A&HCI
Zečević K, Popović N, Vuksanović Božarić A, Vukmirović M, Rizzo M, Muzurović ETiming Is Important—Management of Metabolic Syndrome According to the Circadian RhythmBiomedicines
2023SCI, SCIE, SSCI, A&HCI
Salmen T, Serbanoiu L-I, Bica I-C, Serafinceanu C, Muzurović E, Janez A, Busnatu S, Banach M, Rizvi AA, Rizzo M, Pantea Stoian AA Critical View over the Newest Antidiabetic Molecules in Light of Efficacy—A Systematic Review and Meta-AnalysisIJMS
2023SCI, SCIE, SSCI, A&HCI
Bica I-C, Stoica RA, Salmen T, Janež A, Volčanšek Š, Popovic D, Muzurovic E, Rizzo M, Stoian APThe Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled TrialsMedicina
2023SCI, SCIE, SSCI, A&HCI
Giglio RV, Muzurović EM, Patti AM, Toth PP, Agarwal MA, Almahmeed W, Klisic A, Ciaccio M, Rizzo MTreatment with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i): Current Evidence for Expanding the Paradigm? J Cardiovasc Pharmacol Ther
2023SCI, SCIE, SSCI, A&HCI
Bokan V, Muzurović E, Nejkov S, Rizzo M, Papanas NQuality of Life in People with Diabetes Mellitus and Unilateral Transtibial Amputation - Aspects of Using the Berg Balance ScaleThe International Journal of Lower Extremity Wounds
2023SCI, SCIE, SSCI, A&HCI
Emir Muzurović, Volkan Demirhan Yumuk, Manfredi RizzoGLP-1 and dual GIP/GLP-1 receptor agonists in overweight/obese patients for atherosclerotic cardiovascular disease prevention: Where are we now?Journal of Diabetes and its Complications
2022SCI, SCIE, SSCI, A&HCI
Emir Muzurović, Milena Cojić, Zoja Stanković and Andrej JanežEpicardial Adipocyte-derived TNF-α Modulates Local Inflammation in Patients with Advanced Coronary Artery Disease Current Vascular Pharmacology
2022SCI, SCIE, SSCI, A&HCI
Muzurović, E., Tomšić, K.Z., Vujošević, S. and Petakov, M.Parathyroid hormone and calcitonin response during the calcium infusion test in patients with primary hyperparathyroidismHormones
2022SCI, SCIE, SSCI, A&HCI
Nahum Méndez-Sánchez, Elisabetta Bugianesi, Robert G Gish, Frank Lammert, Herbert Tilg, Mindie H Nguyen, Shiv K Sarin, Núria Fabrellas, Shira Zelber-Sagi, Jian-Gao Fan, Gamal Shiha, Giovanni Targher, Ming-Hua Zheng, Wah-Kheong Chan, Shlomo Vinker, Takumi Kawaguchi, Laurent Castera, Yusuf Yilmaz, Marko Korenjak, C Wendy Spearman, Mehmet Ungan, Melissa Palmer, Mortada El-Shabrawi, Hans-Juergen Gruss, Jean-François Dufour, Anil Dhawan, Heiner Wedemeyer, Jacob George, Luca Valenti, Yasser Fouad, Manuel Romero-Gomez , Mohammed Eslam , Global multi-stakeholder consensus on the redefinition of fatty liver diseaseGlobal multi-stakeholder endorsement of the MAFLD definition Lancet Gastroenterol Hepatol
2022SCI, SCIE, SSCI, A&HCI
Muzurović E, Peng CC, Belanger MJ, Sanoudou D, Mikhailidis DP, Mantzoros C.Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors.Hypertension
2022SCI, SCIE, SSCI, A&HCI
Janez A, Muzurovic E, Stoian AP, Haluzik M, Guja C, Czupryniak L, Duvnjak L, Lalic N, Tankova T, Bogdanski P, Papanas N, Nunes JS, Kempler P, Fras Z, Rizzo MTranslating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert groupInt J Cardiol
2022SCI, SCIE, SSCI, A&HCI
Muzurović E, Borozan S, Vujošević S, Gurnell MThyroid status and vascular risk: an updateCurr Vasc Pharmacol
2022SCI, SCIE, SSCI, A&HCI
Muzurović E, Rizzo M, Mikhailidis DPObesity and nonalcoholic fatty liver disease in type 1 diabetes mellitus patientsJ Diabetes Complications
2022SCI, SCIE, SSCI, A&HCI
Muzurović EM, Volčanšek Š, Tomšić KZ, Janež A, Mikhailidis DP, Rizzo M, Mantzoros CSGlucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current EvidenceJ Cardiovasc Pharmacol Ther
2021SCI, SCIE, SSCI, A&HCI
Emir M Muzurović, Dimitri P MikhailidisDiabetes Mellitus and Noncardiac Atherosclerotic Vascular Disease-Pathogenesis and Pharmacological Treatment OptionsJ Cardiovasc Pharmacol Ther
2021SCI, SCIE, SSCI, A&HCI
Darko Kastelan, Emir Muzurovic, Tina DusekApproach to patients with European Network for the Study of Adrenal Tumor stages I and II adrenocortical carcinomasCurr Opin Endocrinol Diabetes Obes
2021SCI, SCIE, SSCI, A&HCI
Emir Muzurović, Aart J van der Lely, Mark GurnellAST to ALT Ratio and Peripheral Arterial Disease in a Hypertensive Population-Is There a Link?Angiology
2021SCI, SCIE, SSCI, A&HCI
Emir M Muzurović, Snežana Vujošević, Dimitri P MikhailidisCan We Decrease Epicardial and Pericardial Fat in Patients With Diabetes?J Cardiovasc Pharmacol Ther
2021SCI, SCIE, SSCI, A&HCI
Emir Muzurović, Dimitri P Mikhailidis, Christos MantzorosNon-Alcoholic Fatty Liver Disease, Insulin Resistance, Metabolic Syndrome and their Association with Vascular RiskMetabolism
2021SCI, SCIE, SSCI, A&HCI
Emir Muzurović, Brigita Smolović, Mirjana Miladinović, Damir Muhović, Branko ČamparDiagnosis and treatment of mediastinal ectopic thyroid tissue with normally located thyroid gland and primary hyperparathyroidism: a case reportGland Surgery
2021SCI, SCIE, SSCI, A&HCI
Emir M Muzurović, Sanja BorozanRe: Iglay K, Hannachi H, Engel SS, et al. Comorbidities in type 2 diabetes patients with and without atherosclerotic cardiovascular disease: a retrospective database analysis. Curr Med Res Opin. 2021. DOI:10.1080/03007995.2021.1895736Curr Med Res Opin
2021SCOPUS
Emir Muzurović, Sanja Medenica, Milovan Kalezić, Siniša PavlovićPrimary hyperparathyroidism associated with acquired long QT interval and ventricular tachycardiaEndocrinol Diabetes Metab Case Rep
2020SCI, SCIE, SSCI, A&HCI
Emir Muzurović, Siniša Dragnić, Sanja Medenica, Brigita Smolović, Predrag Bulajić, Dimitri P MikhailidisWeight-centric pharmacological management of type 2 diabetes mellitus - An essential component of cardiovascular disease preventionJ Diabetes Complications
2020SCI, SCIE, SSCI, A&HCI
Emir Muzurović, Dimitri P Mikhailidis, Christos MantzorosCommentary: From mice to men: In search for dietary interventions to form the background on which pharmacotherapy for non-alcoholic fatty liver disease should be basedMetabolism
2020SCI, SCIE, SSCI, A&HCI
Emir Muzurović, Dimitri P MikhailidisImpact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profileExpert opinion on pharmacotherapy
2020SCI, SCIE, SSCI, A&HCI
Emir Muzurović, Brigita Smolović, Snežana Vujošević, Milan PetakovEditorial on Prevalence, Diagnosis and Treatment with 3 Different Statins of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?Curr Vasc Pharmacol
2020SCI, SCIE, SSCI, A&HCI
Emir Muzurović, Zoja Stanković, Zlata Kovačević, Benida Šahmanović Škrijelj, Dimitri P Mikhailidis Inflammatory Markers Associated With Diabetes Mellitus - Old and New PlayersCurr Pharm Des
2020SCI, SCIE, SSCI, A&HCI
Emir Muzurović, Ivana Kraljević, Mirsala Solak, Siniša Dragnić, Dimitri P MikhailidisHomocysteine and diabetes: Role in macrovascular and microvascular complicationsJ Diabetes Complications
2016SCOPUS
EMIR MUZUROVIĆ, SNEŽANA VUJOŠEVIĆ, MARINA RATKOVIĆ , DANILO RADUNOVIĆ and DRAGICA BOŽOVIĆTHE IMPACT OF SECONDARY HYPERPARATHYROIDISM ON ECHOCARDIOGRAPHIC PARAMETERS IN HEMODIALYSIS PATIENTSActa Med Croatica

Obavjestenja iz nastave